Insider trading

Period: 120 months Stock: PBYI Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

39 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

39 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

39 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

39 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
39 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
39 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

39 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
14 Sep 2026
Sold on a plan
$566.99K 62,150 at 9.12
52.3%
Sold half or more
6 Jul 2026
AUERBACH ALAN H President and CEO
Sold on a plan
$364.05K 44,058 at 8.26
0.6%
Planned (10b5-1)
12 Jun 2026
Sold on a plan
$194.31K 27,000 at 7.20
50.0%
Sold half or more
12 Jun 2026
MOYES JAY M Director
Sold on a plan
$158.80K 22,000 at 7.22
27.4%
Planned (10b5-1)
7 Jan 2026
AUERBACH ALAN H President and CEO
Sold on a plan
$105.89K 18,012 at 5.88
0.3%
Planned (10b5-1)
2 Jan 2025
AUERBACH ALAN H President and CEO
Sold on a plan
$106.66K 33,841 at 3.15
0.5%
Planned (10b5-1)
3 Jan 2024
AUERBACH ALAN H President and CEO
Sold on a plan
$185.70K 41,396 at 4.49
0.6%
Planned (10b5-1)
3 Jul 2023
AUERBACH ALAN H President and CEO
Sold on a plan
$200.98K 60,698 at 3.31
0.9%
Planned (10b5-1)
3 Jan 2023
AUERBACH ALAN H President and CEO
Sold, plan not stated
$113.81K 27,241 at 4.18
0.4%
11 Jun 2021
Sold, plan not stated
$457.76K 40,993 at 11.17
100%
Sold half or more
10 Jun 2021
Sold, plan not stated
$292.43K 25,748 at 11.36
98.7%
Sold half or more
10 Jun 2021
MOYES JAY M Director
Sold, plan not stated
$286.86K 25,248 at 11.36
80.0%
Sold half or more
10 Jun 2021
Miller Ann Calby Director
Sold, plan not stated
$147.16K 12,874 at 11.43
50.0%
Sold half or more
4 Jan 2021
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$186.38K 18,235 at 10.22
0.4%
11 Jun 2020
Sold, plan not stated
$251.69K 25,245 at 9.97
49.2%
22 Jul 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$126.85K 12,715 at 9.98
0.3%
22 Jan 2019
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$218.33K 8,825 at 24.74
0.2%
20 Jul 2018
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$651.02K 12,520 at 52.00
0.3%
22 Jan 2018
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$991.68K 10,692 at 92.75
0.3%
22 Jan 2018
Lo Steven Chief Commercial Officer
Sold, plan not stated
$172.52K 1,858 at 92.85
6.8%
22 Jan 2018
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$172.52K 1,860 at 92.75
6.8%
1 Dec 2017
EYLER CHARLES R SEE REMARKS
Sold, plan not stated
$139.42K 1,322 at 105.46
4.4%
29 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$1.80M 15,000 at 120.00
35.5%
7 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$1.40M 14,000 at 100.10
33.9%
6 Sep 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$100.00K 1,000 at 100.00
3.5%
20 Jul 2017
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated 2×
$1.25M 13,175 at 94.73
0.3%
20 Jul 2017
Lo Steven Chief Commercial Officer
Sold, plan not stated
$188.85K 1,990 at 94.90
6.8%
20 Jul 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated 2×
$188.78K 1,998 at 94.48
6.8%
3 Jul 2017
BRYCE RICHARD PAUL SR VP, CLINICAL RESEARCH & DEV
Sold, plan not stated
$435.50K 5,000 at 87.10
14.6%
12 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$7.05M 88,944 at 79.31
2.3%
9 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$4.71M 58,316 at 80.77
1.5%
8 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$8.09M 100,000 at 80.95
2.5%
5 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 7×
$28.04M 307,128 at 91.29
7.2%
2 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated
$2.53M 30,475 at 83.06
0.7%
1 Jun 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 2×
$13.98M 169,525 at 82.45
3.8%
26 May 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 3×
$23.12M 300,000 at 77.07
6.3%
25 May 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 4×
$31.15M 400,000 at 77.87
7.8%
24 May 2017
ADAGE CAPITAL PARTNERS GP, L.L.C. 10% owner · indirect
Sold, plan not stated 7×
$38.88M 535,700 at 72.57
9.4%
20 Jan 2017
AUERBACH ALAN H PRESIDENT AND CEO
Sold, plan not stated
$339.06K 10,202 at 33.24
0.2%
Showing 1–39 of 39.